Allison R.  Eberly, PhD

Allison R. Eberly, PhD

Assistant Professor, Pathology & Immunology


  • Laboratory & Genomic Medicine

Additional Titles

  • Assistant Medical Director of Clinical Microbiology, Barnes Jewish Hospital
  • Microbiology Laboratory Liaison, Memorial Hospital Belleville & Shiloh, Alton Memorial Hospital, Christian Hospital, and Parkland Hospital
  • Assistant Medical Director of Molecular Infectious Disease Laboratory, Barnes Jewish Hospital


  • BS: Chemistry and Molecular Biology, Chestnut Hill College, Philadelphia, PA (2014)
  • PhD: Microbiology and Immunology, Vanderbilt University, Nashville, TN (2019)
  • Fellowship, Clinical Microbiology: Mayo Clinic, Rochester, MN (2021)

Board Certifications

  • Diplomate, American Board of Medical Microbiology, 2021

Clincal Interests

  • Microbiology
  • Molecular diagnostics of infectious diseases
  • Mycobacteriology
  • Nontuberculosis mycobacteria (NTM) infections
  • Sexually transmitted infections (STIs)
  • Optimizing test utilization

Research Interests

My research interests include developing and implementing more rapid and accurate diagnostic tests for infections that are under-/misdiagnosed. One example of such infections is nontuberculous mycobacteria (NTM) , which often cause chronic pulmonary infections and require extended multi-drug regimens for treatment. Because NTMs like Mycobacterium avium complex (MAC) are slow-growing microorganisms and phenotypic susceptibility testing is performed only in reference laboratories, the timeline to diagnosis and appropriate treatment is several weeks. There is a need for rapid and accurate identification and susceptibility profiles of NTM from positive broth cultures and directly from patient specimens. Molecular testing is one method that can be utilized to improve the time to diagnosis and treatment.  

Selected Publications

Core Genome Multilocus Sequence Typing and Antibiotic Susceptibility Prediction from Whole-Genome Sequence Data of Multidrug-Resistant Pseudomonas aeruginosa Isolates. Cunningham SA, Eberly AR, Beisken S, Posch AE, Schuetz AN, Patel R. Microbiol Spectr. 2022 Dec 21;10(6):e0392022. doi: 10.1128/spectrum.03920-22. Epub 2022 Nov 9. PMID: 36350158
Development and Validation of a Novel Anaerobic Carbapenem Inactivation Method (Ana-CIM) for the Detection of Carbapenemase Production in Bacteroides fragilis. Eberly AR, Wallace MA, Shannon S, Heitman AK, Schuetz AN, Burnham CD, Jean S. J Clin Microbiol. 2022 Apr 20;60(4):e0218821. doi: 10.1128/jcm.02188-21. Epub 2022 Mar 22. PMID: 35313739
Lord of the “rings”: A case of Plasmodium falciparum. Li M, Comba IY, Eberly AR, Abu Saleh OM. IDCases. 2022 Jan 19;27:e01407. doi: 10.1016/j.idcr.2022.e01407. eCollection 2022. PMID: 35106283
Understanding and Application of Daptomycin-Susceptible Dose-Dependent Category for Enterococcus: A Mixed-Methods Study. Adema JL, Lake LN, Stevens RW, Hogan BM, Schuetz AN, Tande AJ, Mara KC, Eberly AR, Rivera CG. Open Forum Infect Dis. 2022 Jan 10;9(1):ofab611. doi: 10.1093/ofid/ofab611. eCollection 2022 Jan. PMID: 35036465
A tale of two unusual anaerobic bacterial infections in an immunocompetent man: A case report and literature review. Chesdachai S, Eberly AR, Razonable RR. Anaerobe. 2021 Oct;71:102416. doi: 10.1016/j.anaerobe.2021.102416. Epub 2021 Jul 20. PMID: 34293443
Performance of three polymerase chain reaction-based assays for detection of SARS-CoV-2 in different upper respiratory tract specimens. Eberly AR, Germer JJ, Boerger AC, Fernholz EC, Binnicker MJ, Yao JD.
Diagn Microbiol Infect Dis. 2021 Oct;101(2):115441. doi: 10.1016/j.diagmicrobio.2021.115441. Epub 2021 May 28. PMID: 34186320
Cytochrome bd promotes Escherichia coli biofilm antibiotic tolerance by regulating accumulation of noxious chemicals. Beebout CJ, Sominsky LA, Eberly AR, Van Horn GT, Hadjifrangiskou M. NPJ Biofilms Microbiomes. 2021 Apr 16;7(1):35. doi: 10.1038/s41522-021-00210-x. PMID: 33863914
Initial SARS-CoV-2 PCR crossing point does not predict hospitalization and duration of PCR positivity.
Eberly AR, Challener DW, Shweta FNU, Fida M, Boerger AC, Assi M, O’Horo JC, Binnicker MJ. J Microbiol Immunol Infect. 2021 Feb;54(1):77-80. doi: 10.1016/j.jmii.2020.08.020. Epub 2020 Oct 10. PMID: 33069621
Data highlighting phenotypic diversity of urine-associated Escherichia coli isolates. Eberly AR, Beebout CJ, Tong CMC, Van Horn GT, Green HD, Fitzgerald MJ, De S, Apple EK, Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA, Clayton DB, Stratton CW, Schmitz JE, Hadjifrangiskou M. Data Brief. 2020 Jun 3;31:105811. doi: 10.1016/j.dib.2020.105811. eCollection 2020 Aug. PMID: 32566710
Defining a Molecular Signature for Uropathogenic versus Urocolonizing Escherichia coli: The Status of the Field and New Clinical Opportunities. Eberly AR, Beebout CJ, Carmen Tong CM, Van Horn GT, Green HD, Fitzgerald MJ, De S, Apple EK, Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA, Clayton DB, Stratton CW, Schmitz JE, Hadjifrangiskou M. J Mol Biol. 2020 Feb 14;432(4):786-804. doi: 10.1016/j.jmb.2019.11.008. Epub 2019 Nov 30.
PMID: 31794727

Dionne Brierton
BJCIH Room 5800